Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ticagrelor versus aspirin after CABG for prevention of major cardiovascular events
2012-003630-16Phase 3Terminated
- Sponsor
- Deutsches Herzzentrum München
- Start
- Jan 2013
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in atherosclerotic disease and coronary arteriosclerosis comparing Ticagrelor arm with Aspirin arm (2 arms). Primary endpoint: Major adverse cardiovascular and cerebrovascular events composite. Started Jan 2013; status: terminated.
02
Drugs
ticagreloraspirin
03
Conditions
atherosclerotic diseasecoronary arteriosclerosis
Beyond the preview
Go deeper on 2012-003630-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-003630-16.